Home > News > Nanogen and Epoch Biosciences Agree to Merge
September 7th, 2004
Nanogen and Epoch Biosciences Agree to Merge
Abstract:
Nanogen, Inc. (Nasdaq: NGEN), a developer of advanced in vitro diagnostic products, and Epoch Biosciences, Inc. (Nasdaq: EBIO), a provider of proprietary products that accelerate genomic analysis, announced today the signing of a definitive agreement to merge Epoch into Nanogen in an all-stock transaction. Epoch has a variety of products that are complementary to Nanogen's, and the merger will expand Nanogen's reach in the rapidly growing clinical lab and research markets.
Source:
corporate-ir
Bookmark:
Investments/IPO's/Splits
Elsevier Business Intelligence (EBI) to Host 'IN3 Medical Device 360 Boston,' June 24-26, 2013 May 20th, 2013
Aspen Aerogels Announces $22.5 Million Private Placement May 18th, 2013
Harris & Harris Group Notes the Sale of a Second D-Wave Quantum Computer May 16th, 2013
Nanometrics Announces Upcoming Investor Events May 14th, 2013
Announcements
UofL scientists uncover how grapefruits provide a secret weapon in medical drug delivery May 22nd, 2013
Atomic-Scale Investigations Solve Key Puzzle of LED Efficiency: MIT and Brookhaven Lab scientists use electron microscopy imaging techniques to settle a solid-state controversy and raise new experimental possibilities May 22nd, 2013
Single-Cell Transfection Tool Enables Added Control for Biological Studies: McCormick researchers develop method of delivering molecules into targeted cells May 22nd, 2013
Rice unveils method for tailoring optical processors: Arranging nanoparticles in geometric patterns allows for control of light with light May 21st, 2013